Advantages and disadvantages of trial designs: A review of analysis methods for ICD studies

PACE - Pacing and Clinical Electrophysiology

Volumn 23, Issue 6, 2000, Pages 1029-1038

  Hallstrom, Alfred P ^a   Anderson, Jeffrey L ^b   Cobb, Leonard A ^c   Friedman, Peter L ^d   Herre, John M ^e   Klein, Richard C ^h   Mcanulty, John ^f   Steinberg, Jonathan S ^g  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Cape Cod   (United States)

^e SENTARA NORFOLK GENERAL HOSPITAL   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^h NONE

Author keywords

Analytic methods; Arrhythmia; Bias; ICD; Study design

Indexed keywords

ANALYTIC METHOD; DATA BASE; DEFIBRILLATOR; FEMALE; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PEDAGOGICS; REVIEW; SURVIVAL;

EID: 0034130974     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2000.tb00892.x     Document Type: Review

References (34)

1. 1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. New Engl J Med 1989; 321:406-412.
2. 2. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: The CAPS. Am J Cardiol 1988; 61:501-509.
3. 3. Fogoros RN, Elson JJ, Bonnet CA. Actuarial incidence and pattern of occurrence of shocks following implantation of the automatic implantable defibrillator. PACE 1989; 11:1465-1473.
4. 4. Fogoros RN, Elson JJ, Bonnet CA, et al. Efficacy of the automatic implantable cardioverter defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol 1990; 16:381-386.
5. 5. Meissner MD, Lehmann MH, Steinman RT, et al. Ventricular fibrillation in patients without significant structural heart disease: A multicenter experience with implantable cardioverter-defibrillator therapy. J Am Coll Cardiol 1993; 21:1406-1412.
6. 6. Fan, W, Peter CT on behalf of the CEDARS Investigators. Survival and incidence of appropriate shocks in implantable cardioverter defibrillator recipients who have no detectable structural heart disease. Am J Cardiol 1994; 74:687-690.
7. 7. Sweeney MO, Ruskin JN, Garan H, et al. Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. Circulation 1995; 92:3273-3281.
8. 8. Wever EFD, Hauer RNW, van Capelle FJL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995; 91:2195-2203.
9. 9. Newman D, Sarve MJ, Herre J, et al. Survival after implantation of the cardioverter defibrillator. Am J Cardiol 1992; 69:899-903.
10. 10. Kim SG, Fogoros RN, Furman S, et al. Standardized reporting of implantable cardioverter-defibrillator patient outcome: The report of a North American Society of Pacing and Electrophysiology Policy Conference, February 9-10, 1993. PACE 1993; 16:1358-62.
11. 11. Chnue CW, Soo KG, Fisher JD, et al. Comparison of defibrillator therapy and other therapeutic modalities for sustained ventricular tachycardia or ventricular fibrillation associated with coronary artery disease. Am J Cardiol 1994; 73:1075-1079.
12. 12. Sweeney MO, Ruskin JN. Mortality benefits and the implantable cardioverter-defibrillator. Circulation 1994; 89:1851-1858.
13. 13. Cobb LA, Weaver WD, Fahrenbrach CE, et al. Community-based interventions for sudden cardiac death: Impact, limitations, and changes. Circulation 1992; 85(Suppl.):I-98-I-102.
14. 14. Siebels J, Kuck KH, and the CASH Investigators. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study, Hamburg). Am Heart J 1994; 127:1139-44.
15. 15. Moss A, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335:1933-1340.
16. 16. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal sustained ventricular arrhythmias. N Engl J Med 1997; 337:1576-1583.
17. 17. Bigger JT Jr. Prophylactic use of implanted cardiac: defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997; 337:1569-1575.
18. 18. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): Study Design and Organization. Am J Cardiol 1993; 72:103F-108F.
19. 19. Bardy GH, Lee KL, Mark DB, et al. The Sudden Cardiac Death in Heart Failure Trial: pilot study. (abstract) PACE 1997; 20:1148.
20. 20. Temple R. Difficulties in evaluating positive control trials. Biopharmaceutical Section, Proceedings of the American Statistical Association. Arlington, VA, American Statistical Association, 1983, pp. 1-7.
21. 21. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol 1993; 72:280-287.
22. 22. Mason JW, for the ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachycardia. N Engl J Med 1993; 329:452-458.
23. 23. Epstein AE, Hallstrom AP, Rogers WJ, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainido, and moricizine after myocardial infarction. JAMA 993; 270:2451-2455.
24. 24. Teo KK, Yusuf S, Furbert CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993; 270:1589-1595.
25. 25. Buxton AE, Lee KL, Fisher JD, ut al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341:1882-1890.
26. 2G. Gibaldi M, Sullivan S. Intention-to-treat analysis in randomized trials: Who gets counted? J Clin Pharmacol 1997; 37:667-672.
27. 27. Every NR, Hlatky MA, McDonald KM, et al. Estimating the proportion of post-myorardial infarction patients who may benefit from prophylactic implantable defibrillator placement: An evaluation of the CAST Registry. Am J Cardiol 1998; 82:683-085.
28. 28. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii:349-360.
29. 20. TIMI IIIB Investigators. Effects of tissue plasminognn activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Circulation 1994; 89:1545-1556.
30. 30. Fibrinolytic Therapy Trialists' Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction. Lancet 1994; 343:311-322.
31. 31. ISIS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-685.
32. 32. Julian DG, Camm AJ, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349:667-674.
33. 33. The CABG Patch Trial Investigators and Coordinators. The Coronary Artery Bypass Graft (CABG) Patch Trial. Prog Cardiovasc Dis 1993; 36:97-114.
34. 34. The AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators (AVID)-rationale, design, and methods. Am J Cardiol 1995; 75:470-475.